ABVC BioPharma
ABVC
13 hedge funds and large institutions have $792K invested in ABVC BioPharma in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.31% less ownership
Funds ownership: 3.52% → 3.21% (-0.31%)
7% less funds holding
Funds holding: 14 → 13 (-1)
57% less capital invested
Capital invested by funds: $1.82M → $792K (-$1.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$34.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.1K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$20.2K |
| 4 |
Squarepoint
New York
|
+$17.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$118K |
| 2 |
Renaissance Technologies
New York
|
-$31.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$24K |
| 4 |
Jane Street
New York
|
-$18K |
| 5 |
Morgan Stanley
New York
|
-$11K |
ABVC Hedge Fund Activity: Q1 2026 in Review
13 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2026, worth a combined $792K — down 57% from $1.82M a quarter earlier.
Fund positioning in ABVC was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $34.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $118K sold.
- 13 institutional investors held ABVC BioPharma (ABVC) as of Q1 2026, down from 14 in Q4 2025.
- Funds reported $792K of ABVC BioPharma stock for Q1 2026, down 57% quarter-over-quarter.
- 6 funds opened new ABVC BioPharma positions in Q1 2026 and 6 closed out, a net change of 0 holders.
- The largest ABVC BioPharma buyer in Q1 2026 was Two Sigma Securities, an estimated $34.8K added.
- The largest ABVC BioPharma seller in Q1 2026 was Citadel Advisors, an estimated $118K sold.
Based on aggregated 13F filings for Q1 2026.